Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note published on Thursday morning. The brokerage issued a sell rating on the stock.

A number of other equities research analysts have also recently weighed in on SYRS. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Piper Sandler reissued an “overweight” rating and set a $5.00 price objective (down previously from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Stock Up 12.8 %

SYRS opened at $0.29 on Thursday. The firm has a market cap of $7.87 million, a price-to-earnings ratio of -0.10 and a beta of 1.59. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The firm’s 50-day simple moving average is $1.85 and its 200-day simple moving average is $3.57. Syros Pharmaceuticals has a twelve month low of $0.18 and a twelve month high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter in the prior year, the firm earned ($1.35) EPS. Equities research analysts anticipate that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insider Buying and Selling

In other Syros Pharmaceuticals news, CFO Jason Haas bought 35,363 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was bought at an average price of $1.55 per share, for a total transaction of $54,812.65. Following the transaction, the chief financial officer now owns 59,915 shares of the company’s stock, valued at approximately $92,868.25. The trade was a 144.03 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Conley Chee purchased 50,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was bought at an average cost of $1.51 per share, for a total transaction of $75,500.00. Following the purchase, the chief executive officer now owns 72,504 shares in the company, valued at $109,481.04. This trade represents a 222.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 130,707 shares of company stock worth $206,491 over the last three months. 12.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Opaleye Management Inc. raised its holdings in Syros Pharmaceuticals by 119.1% in the first quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock worth $4,213,000 after purchasing an additional 428,175 shares during the period. Kennedy Capital Management LLC acquired a new stake in Syros Pharmaceuticals during the 1st quarter worth $2,166,000. Vanguard Group Inc. lifted its holdings in Syros Pharmaceuticals by 21.3% during the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after acquiring an additional 163,234 shares in the last quarter. Certuity LLC acquired a new position in Syros Pharmaceuticals in the second quarter valued at about $109,000. Finally, Acadian Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after acquiring an additional 17,416 shares in the last quarter. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.